Overview


According to FutureWise analysis the market for antisense oligonucleotides in 2023 is US$ 2.12 billion, and is expected to reach US$ 4.73 billion by 2031 at a CAGR of 10.50%.

Antisense oligonucleotides, also called ASOs or AONs, are small molecules used to prevent or alter the production of proteins. These ASOs consist of short, single-stranded DNA fragments with complementary sequences to a specific mRNA. Proteins serve as the essential workforce within cells, overseeing various cellular processes. They are made in a two-step process: first, a specific gene responsible for encoding a particular protein is converted into a messenger RNA (mRNA), which serves as an instructional blueprint. This mRNA carries the genetic information from the gene to the cellular compartment responsible for protein synthesis. Within this compartment, the mRNA's instructions are translated into the corresponding protein. ASOs can also recruit cellular machinery that leads to the degradation of the targeted mRNA. This further prevents the production of the corresponding protein.

ASOs have various applications in treating various diseases, including ocular disease, cancer, diabetes, Amyotrophic Lateral Sclerosis (ALS), etc. ASOs have been analyzed as a potential treatment for certain ocular diseases. They can be developed to target specific genetic mutations associated with conditions like inherited retinal disorders or other ocular diseases. Also, cancer therapy targets specific genes or gene products involved in the growth or progression of cancer. Moreover, ASOs have been examined for their potential in treating diabetes, especially in cases where specific genetic factors contribute to the disease. They target genes associated with insulin production, insulin sensitivity, or other factors applicable to glucose metabolism.

FutureWise Market Research has published a report that provides an insightful analysis antisense oligonucleotides market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts antisense oligonucleotides market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Isarna Therapeutics GmbH.
  • Arrowhead Pharmaceuticals, Inc.
  • Atlantic Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Gene Signal International SA
  • GlaxoSmithKline plc.
  • Geron Corporation
  • Gradalis
  • ICO Therapeutics
  • Aptose Biosciences
  • Marina Biotech
  • MiRagen Therapeutics, Inc.
  • Synlogic, Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmaxis Ltd.
  • Regulus Therapeutics Inc.
  • Rexahn Pharmaceuticals, Inc.
  • RXi Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing prevalence of genetic disorders and rare diseases is expected to drive the antisense oligonucleotide therapies significantly. These innovative treatments hold immense potential to address diverse genetic disorders. By leveraging accurate targeting at the molecular level, antisense oligonucleotides exhibit a distinctive capability to modulate gene expression, offering a highly promising route for therapeutic intervention. This rise in demand is underpinned by a growing awareness of the genetic underpinnings of diseases, bolstering confidence in the effectiveness of these therapies across a spectrum of genetic disorders. Additionally, continuous advancements in molecular biology techniques further propel the development of highly efficient antisense oligonucleotides, thereby driving the market. These advancements include many innovations, including improved synthesis methods, delivery systems, and a deeper understanding of nucleic acid interactions. Such advancement has allowed scientists and researchers to design oligonucleotides more precisely and effectively, targeting specific genetic sequences, leading to heightened therapeutic potential. Also, the growing trend of collaborations within the antisense oligonucleotides market represents a compelling opportunity for accelerated innovation and advancement. Businesses may tap into a reservoir of collective expertise and resources by merging forces with academic institutions, research organizations, and fellow companies. This collaborative approach facilitates a dynamic exchange of knowledge, ideas, and technical abilities, expediting the development and improvement of antisense oligonucleotide therapies. However, the high research and development costs of antisense oligonucleotides significantly hinder market accessibility, particularly for smaller companies. The vast resources required for pre-clinical testing, clinical trials, and regulatory approvals may be prohibitively costly, deterring many potential entrants from seeking development in this field. This financial barrier may lead to a concentration of research and innovation among larger, more financially robust pharmaceutical companies, potentially suppressing diversity and competition within the market.

By Drug

  • Approved Drugs
    • Pegaptanib
    • Mipomersen
    • Eteplirsen
  • Pipeline Analysis

By Indication

  • Ocular Diseases
  • Cancer
  • Diabetes
  • Amyotrophic Lateral Sclerosis (ALS)
  • Duchenne Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Others

By Application

  • Basic Research
  • Genomics
  • Target Validation
  • Drug Discovery

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to the rising demand for antisense oligonucleotides, strong product pipeline, an increasing number of FDA approvals, growing diseases such as ocular disease, diabetes, AIDS, and cancer, technological advancements, well-developed healthcare infrastructure, and rising patient population in the US is likely to drive the growth of the market. Additionally, increasing research and development activities, an increase in investment for developing new and advanced technologies, and an increasing number of launches of novel antisense oligonucleotide products by major players in the market. Therefore, the above-mentioned factors are anticipated to propel the growth of the antisense oligonucleotides market during the forecast period in the area.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

• To provide with an exhaustive analysis on the Antisense Oligonucleotides Market By Drug, By Indication, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antisense Oligonucleotides Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antisense Oligonucleotides Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antisense Oligonucleotides Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antisense Oligonucleotides Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Approved Drugs
         1.1. Pegaptanib
         1.2. Mipomersen
         1.3. Eteplirsen
        2. Pipeline Analysis

  • 8.   Antisense Oligonucleotides Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Ocular Diseases
        2. Cancer
        3. Diabetes
        4. Amyotrophic Lateral Sclerosis (ALS)
        5. Duchenne Muscular Dystrophy
        6. Spinal Muscular Atrophy
        7. Others

  • 9.   Antisense Oligonucleotides Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Basic Research
        2. Genomics
        3. Target Validation
        4. Drug Discovery

  • 10.   North America Antisense Oligonucleotides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antisense Oligonucleotides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antisense Oligonucleotides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antisense Oligonucleotides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ionis Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sarepta Therapeutics
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Biogen
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Alnylam Pharmaceuticals, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Antisense Therapeutics Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Isarna Therapeutics GmbH.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Arrowhead Pharmaceuticals, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Atlantic Pharmaceuticals, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Enzon Pharmaceuticals, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Bio-Path Holdings, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Gene Signal International SA
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. GlaxoSmithKline plc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Geron Corporation
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Gradalis
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. ICO Therapeutics
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Aptose Biosciences
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Marina Biotech
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. MiRagen Therapeutics, Inc.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Synlogic, Inc.
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. OncoGenex Pharmaceuticals Inc.
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Pharmaxis Ltd.
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Regulus Therapeutics Inc.
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Rexahn Pharmaceuticals, Inc.
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. RXi Pharmaceuticals
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients